GLP-1 Drugs and Pregnancy: When to Stop, What the Data Shows, and PCOS Considerations

GLP-1 drugs and pregnancy involve three distinct situations that require different framings:

1. Patients planning pregnancy: When to stop, how far in advance, and what happens to weight
2. Patients who become pregnant while on a GLP-1: The unexpected-pregnancy scenario
3. PCOS patients: Where GLP-1 therapy intersects with fertility restoration

This article covers the published label guidance, the animal reproductive toxicity data, and the PCOS fertility picture. It is awaiting medical-reviewer signoff.

What the prescribing labels say

The Wegovy (semaglutide 2.4 mg) prescribing label states:

"Discontinue Wegovy at least 2 months before a planned pregnancy based on the half-life of semaglutide."

The Zepbound (tirzepatide) label contains the same recommendation — discontinue at least 2 months before planned conception.

This is not a soft recommendation. It is a label-stated instruction with a pharmacokinetic rationale: semaglutide's half-life is approximately 7 days; tirzepatide's is approximately 5 days. At 5 half-lives after the last dose, the drug has reached approximately 3% of peak concentration. The 2-month window ensures complete clearance plus a margin before conception.

Ozempic (semaglutide, T2D label) and Mounjaro (tirzepatide, T2D label) carry equivalent cautions — pregnant women or women planning pregnancy should discuss discontinuation with their prescriber.

The animal reproductive toxicity data

Neither semaglutide nor tirzepatide has been studied in pregnant humans in a controlled trial. The safety signal comes from animal studies required as part of the FDA approval process.

Semaglutide: Rat and rabbit studies at doses producing exposures similar to or below clinical doses showed adverse fetal outcomes including reduced fetal weight, skeletal malformations, and increased early fetal deaths at higher doses. The FDA classifies semaglutide under the current label format as: limited or no data in human pregnancy; animal data suggest risk.

Tirzepatide: Rat reproductive toxicity studies at doses clinically relevant showed reduced fetal body weight and fetal structural abnormalities. Similar animal signal to semaglutide.

The practical meaning: no human data exists confirming safety in pregnancy; animal data gives reason for caution. The label reflects this as a 2-month pre-conception stop recommendation.

What happens if pregnancy occurs while on a GLP-1

Patients who discover they are pregnant while taking a GLP-1 drug should contact their prescriber immediately. The clinical guidance is to stop the drug. The first trimester — when organogenesis is occurring — is the highest-sensitivity period; the priority is prompt discontinuation.

Pregnancy registries: Novo Nordisk operates a voluntary pregnancy registry for inadvertent semaglutide exposure (both Ozempic and Wegovy). Prescribers can enrol patients; the data contributes to post-market safety monitoring. Ask your prescriber if registration is appropriate.

Weight management after stopping: Appetite and weight typically trend back toward baseline after GLP-1 discontinuation (see weight regain guide). This is clinically separate from the pregnancy management question — the immediate priority is stopping the drug; weight management during pregnancy is a separate discussion with the obstetric team.

PCOS: the fertility-restoration dynamic

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility. PCOS is characterised by insulin resistance, elevated androgens, and disrupted ovarian function. GLP-1 therapy improves insulin sensitivity, which can reduce androgen levels, restore menstrual regularity, and resume ovulation in women who were previously not ovulating.

Clinical studies of GLP-1s in PCOS populations (primarily liraglutide and semaglutide) have shown improvements in:

• Menstrual regularity
• Androgen markers (testosterone, DHEAS)
• AMH (anti-Müllerian hormone, a marker of ovarian reserve)
• Ovulation rates in previously anovulatory patients

The implication: a woman with PCOS who starts a GLP-1 drug and was previously anovulatory may resume ovulating without expecting to — and therefore may become pregnant without planning for it. This is not a reason to avoid GLP-1 therapy in PCOS (the metabolic benefits are well-documented); it is a reason to discuss contraception and pregnancy planning explicitly at initiation.

For PCOS patients who are also trying to conceive: GLP-1 therapy pre-conception may improve ovarian function and insulin sensitivity in ways that support fertility. However, the drug should be stopped 2 months before planned conception, per label guidance. Some fertility medicine frameworks use a timed protocol: GLP-1 therapy to restore metabolic health and ovulation, then drug discontinuation and conception window. This is an individualised clinical discussion with a reproductive endocrinologist or fertility specialist.

Breastfeeding

The semaglutide and tirzepatide labels both state that it is unknown whether these drugs are excreted in human breast milk. Given the absence of data and the potential for adverse effects in breastfed infants, the labels recommend avoiding use during breastfeeding.

This is a standard precautionary position for drugs without breastfeeding data. Decisions about GLP-1 therapy during breastfeeding should be made with the prescriber, weighing the clinical benefit to the parent and the potential risk to the infant.

Editorial note: This article awaits medical-reviewer signoff. The guidance here reflects prescribing label content and published safety data; it does not constitute clinical advice. Pregnancy planning and medication decisions during pregnancy and breastfeeding should be made with your prescriber and, as appropriate, an obstetrician or maternal-fetal medicine specialist.